Hemagen Diagnostics, Inc. (HMGN) Research

Hemagen Diagnostics, Inc., a global biotechnology firm, specializes in delivering clinical diagnostic solutions for both human and animal health. The company designs, manufactures, and distributes the VIRGO product line, a series of human clinical immunoassays used for identifying autoimmune and infectious diseases, as well as acute phase proteins. Its comprehensive human diagnostic portfolio also encompasses Universal IFA components, various supplies, controls, calibrators, accessories, H-rotors, reagents, electrodes, equipment, and specialized assays covering conditions such as Chagas, acute phase proteins, and cytokines. For the veterinary market, Hemagen Diagnostics provides diagnostic equipment, reagents, consumables, accessories, and electrodes crucial for chemistry, hematology, and electrolyte analysis. The company reaches a diverse customer base, including laboratories, hospitals, and blood banks, through both direct sales and an extensive distribution network. Established in 1985, Hemagen Diagnostics maintains its headquarters in Columbia, Maryland.

Market snapshot

Symbol
HMGN
Price
$0.00
Day change
0.00%
Market cap
$4.7K
P/E ratio
-0.01x
52-week range
0.0001-0.1251
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • BioSyntech, Inc. (BSYI)
  • Quantum Medical Transport, Inc. (DRWN)
  • E Med Future, Inc. (EMDF)
  • 4Front Ventures Corp. (FFNTF)
  • GelStat Corporation (GSAC)
  • Nascent Biotech, Inc. (NBIO)
  • Qrons Inc. (QRON)
  • RegeneRx Biopharmaceuticals, Inc. (RGRX)

Open Hemagen Diagnostics, Inc. (HMGN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.